NIAMS Clinical Trial Implementation Cooperative Agreement (U01) | PAR 16 447

Opportunity Information: Apply for PAR 16 447

The NIAMS Clinical Trial Implementation Cooperative Agreement (U01) (PAR-16-447) is a National Institutes of Health funding opportunity from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) that supports the actual conduct and execution of investigator-initiated interventional clinical trials across all phases. The intent is to fund trials that are ready to launch and carry through enrollment, intervention delivery, follow-up, data collection, and analysis, rather than early concept development. Because the mechanism is a cooperative agreement (U01), awardees should expect a more collaborative relationship with NIAMS compared with a standard research grant, typically involving NIH scientific or programmatic involvement in monitoring progress, agreeing on milestones, and ensuring the study stays on track.

A key feature of this program is its usual two-part pathway for NIAMS clinical trials. Most applicants are expected to complete an R34 planning phase first (Part 1), then submit a U01 implementation application (Part 2). The R34 stage is generally used to finish the essential groundwork needed before a large clinical trial can responsibly begin, such as finalizing the protocol, establishing study operations, confirming feasibility, developing recruitment and retention strategies, putting data and safety monitoring procedures in place, and preparing regulatory and oversight materials. However, NIAMS also allows investigators to apply directly to the U01 without first receiving an R34 if they can demonstrate that all necessary pre-trial planning and preparation has already been completed through other support or prior work. In practice, that means the U01 application needs to show a strong readiness-to-start posture, with the operational and scientific details sufficiently mature to move into implementation quickly.

NIAMS emphasizes that supported trials should be hypothesis-driven, structured around clear milestones, and positioned for high impact within NIAMS mission areas (arthritis and rheumatic diseases, musculoskeletal diseases, and skin diseases). The “milestone-defined” expectation signals that NIAMS will look for a concrete, measurable project management framework, such as enrollment targets by time period, site activation timelines, adherence to recruitment benchmarks, data quality metrics, and prespecified decision points. The focus on high impact typically implies that the trial’s results should be capable of changing clinical practice, advancing therapeutic strategies, clarifying benefits and risks of an intervention, or substantially improving understanding of treatment approaches in NIAMS-relevant conditions.

Eligibility is broad and includes many types of U.S.-based organizations and governments. Eligible applicants listed for this opportunity include state, county, and city or township governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; Native American tribal governments (federally recognized) and other Native American tribal organizations; public housing authorities/Indian housing authorities; nonprofits with or without 501(c)(3) status (other than institutions of higher education); for-profit organizations (other than small businesses) as well as small businesses; and other categories. The FOA also explicitly calls out additional eligible applicant types such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), faith-based or community-based organizations, regional organizations, eligible federal agencies, Indian/Native American tribal governments that are not federally recognized, and U.S. territories or possessions.

The opportunity includes important limits related to foreign participation. Non-domestic (non-U.S.) entities (foreign organizations and foreign institutions) are not eligible to apply as the applicant organization, and non-domestic components of U.S. organizations are not eligible to apply. At the same time, “foreign components” are allowed as defined in the NIH Grants Policy Statement, meaning a U.S. applicant may include certain types of foreign involvement within the project when justified and compliant with NIH rules (for example, specific performance sites, collaborations, or resources outside the U.S.), even though a foreign institution cannot serve as the primary applicant.

Administratively, the funding instrument is a cooperative agreement (U01) in the health activity category, with CFDA number 93.846. The opportunity is categorized as discretionary funding. The source data provided lists an original closing date of 2018-01-24, and it does not specify an award ceiling or expected number of awards in the excerpt. Overall, this FOA is best understood as NIAMS support for clinical trials that are beyond planning and are prepared for full implementation, with a strong emphasis on well-defined execution milestones and the likelihood of meaningful impact in NIAMS-relevant disease areas.

• The National Institutes of Health in the health sector is offering a public funding opportunity titled "NIAMS Clinical Trial Implementation Cooperative Agreement (U01)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.846.
• This funding opportunity was created on 2016-09-23.
• Applicants must submit their applications by 2018-01-24. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.

Apply for PAR 16 447

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: